IP Library Granted Patent US 8,129,561
Granted Patent B2
US 8,129,561 · App. 12/273,648 · Granted Mar 6, 2012

Processes for intermediates for macrocyclic compounds

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,129,561
App. No.
12/273,648
Granted
Mar 6, 2012
Kind
B2
Abstract

The present invention is directed to novel macrocyclic compounds of formula (I) and their pharmaceutically acceptable salts, hydrates or solvates: wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , n 1 , m, p Z 1 , Z 2 , and Z 3 are as describe in the specification. The invention also relates to compounds of formula (I) which are antagonists of the motilin receptor and are useful in the treatment of disorders associated with this receptor and with or with motility dysfunction.

Claims (41)

1. A process for preparing a compound of formula (I):

wherein R 1 is C 1 -C 4 alkyl; the process comprising:

(a) contacting a compound of formula (A):

with a compound of formula (B):

in the presence of an azodicarboxylate reagent and a phosphine reagent, or in the presence of a combined Mitsunobu reagent, to form a compound of formula (C):

wherein X is halogen or triflate and PG 2 is an ester protecting group;

(b) contacting the compound of formula (C) with a reducing agent to form a compound of formula (D):

(c) contacting the compound of formula (D) with a compound of formula (E):

in the presence of a palladium catalyst, optionally a copper salt and/or optionally an organic base to form a compound of formula (F):

wherein PG 1 is hydrogen or an amine protecting group;

(d) contacting the compound of formula (F) with hydrogen in the presence of a metal catalyst to form the compound of formula (G):

(e) removing the PG 1 protecting group, when present, from the compound of formula (G) to provide the compound of formula (I).

2. The process of claim 1 , wherein the compound of formula (I) is:

3. The process of claim 1 wherein the compound of formula (B) is selected from the group consisting of:

wherein PG 2 is an ester protecting group.

4. The process of claim 1 , wherein X is iodine.

5. The process of claim 1 , wherein PG 1 is hydrogen.

6. The process of claim 1 , wherein PG 1 is a carbamate protecting group.

7. The process of claim 1 , wherein PG 1 is selected from the group consisting of tert-butoxycarbonyl (Boc), benzyloxycarbonyl (Cbz), 9-fluorenylmethoxycarbonyl (Fmoc), α,α-dimethyl-3,5-dimethoxybenzyloxycarbonyl (Ddz) and allyloxycarbonyl (Alloc).

8. The process of claim 1 , wherein PG 2 is an alkyl group or an alkyl group substituted with an aryl group.

9. The process of claim 1 , wherein PG 2 is methyl, ethyl or benzyl.

10. The process of claim 1 , wherein the azodicarboxylate reagent is selected from the group consisting of diethylazodicarboxylate (DEAD) and diisopropylazodicarboxylate (DIAD).

11. The process of claim 1 , wherein the phosphine reagent is selected from the group consisting of triphenylphosphine and tributylphosphine.

12. The process of claim 1 , wherein the combined Mitsunobu reagent is a triphenylphosphine-diisopropylazodicarboxylate (DIAD) adduct.

13. The process of claim 1 , wherein the reducing agent is selected from the group consisting of an aluminum hydride and a borohydride.

14. The process of claim 1 , wherein the reducing agent is selected from the group consisting of diisobutylaluminum hydride (DIBAL-H), lithium aluminum hydride (LAH), and lithium borohydride.

15. The process of claim 1 , wherein the palladium catalyst is selected from the group consisting of dichlorobis(triphenylphosphine)palladium(II), dichlorobis(acetonitrile)-palladium(II), dichlorobis(benzonitrile)palladium(II), tetrakis(triphenyl-phosphine)palladium(0) and tris(dibenzylideneacetone)dipalladium(0).

16. The process of claim 1 , wherein the copper salt is a copper halide.

17. The process of claim 1 , wherein the copper salt is copper (I) iodide.

18. The process of claim 1 , wherein the copper salt is not present.

19. The process of claim 1 , wherein the organic base is selected from the group consisting of a dialkylamine, a trialkylamine and an aromatic amine.

20. The process of claim 1 , wherein the organic base is triethylamine (TEA), diisopropylamine or N,N-diisopropylethylamine (DIPEA).

21. The process of claim 1 , wherein the organic base is not present.

22. The process of claim 1 , wherein (c) is conducted in the presence of a phosphine.

23. The process of claim 1 , wherein the metal catalyst is palladium on carbon or platinum oxide.

24. The process of claim 1 , wherein compound (G) is subjected to a purification step comprising chromatography or dry pack chromatography.

25. The process of claim 1 , wherein contacting the compound of formula (A) with a compound of formula (B) in the presence of an azodicarboxylate reagent and a phosphine reagent, or in the presence of a combined Mitsunobu reagent, to form a compound of formula (C) is replaced by contacting the compound of formula (A) with a compound of formula (G):

wherein Y is a leaving group, R 1 is C 1 -C 4 alkyl and PG 7 is an ester protecting group, in the presence of a base to form the compound of formula (C).

26. The process of claim 25 , wherein Y is a halogen or a sulfonate.

27. The process of claim 25 , wherein Y is selected from the group consisting of 4-methylbenzenesulfonate (tosylate), methanesulfonate (mesylate), 2-nitrobenezenesulfonate, 4-nitrobenezenesulfonate (nosylate), 2,4-dinitrobenezenesulfonate, 4-bromobenezenesulfonate (brosylate), trifluoromethanesulfonate (triflate), chloride, bromide and iodide.

28. The process of claim 25 , wherein the base is selected from the group consisting of a hydrogen carbonate salt, a carbonate salt, a trialkylamine and an aromatic amine.

Assignments (5)
RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 044949, FRAME 0634 Recorded Nov 16, 2023
From: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
To: MALLINCKRODT INTERNATIONAL FINANCE S.A.; MALLINCKRODT CB LLC; MALLINCKRODT FINANCE GMBH; MALLINCKRODT US HOLDINGS LLC (F/K/A MALLINCKRODT US HOLDINGS INC.); MALLINCKRODT CARRIBEAN, INC.; MALLINCKRODT US POOL LLC; MNK 2011 LLC (F/K/A MALLINCKRODT INC.); LUDLOW LLC (F/K/A LUDLOW CORPORATION); CNS THERAPEUTICS, INC.; MALLINCKRODT ENTERPRISES HOLDINGS LLC (F/K/A MALLINCKRODT ENTERPRISES HOLDINGS, INC.); MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; LAFAYETTE PHARMACEUTICALS LLC; LIEBEL-FLARSHEIM COMPANY LLC; MALLINCKRODT BRAND PHARMACEUTICALS LLC (F/K/A MALLINCKRODT BRAND PHARMACEUTICALS, INC.); MALLINCKRODT VETERINARY, INC.; MALLINCKRODT US HOLDINGS LLC; IMC EXPLORATION COMPANY; MEH, INC.; MALLINCKRODT HOSPITAL PRODUCTS IP UNLIMITED COMPANY (F/K/A MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED); MALLINCKRODT ARD IP UNLIMITED COMPANY (F/K/A MALLINCKRODT ARD IP LIMITED); OCERA THERAPEUTICS LLC (F/K/A OCERA THERAPEUTICS, INC.); SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC (F/K/A VTESSE INC.); MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY (F/K/A MALLINCKRODT PHARMA IP TRADING D.A.C.); INFACARE PHARMACEUTICAL CORPORATION; ST SHARED SERVICES LLC; THERAKOS, INC.; IKARIA THERAPEUTICS LLC; INO THERAPEUTICS LLC
Reel/Frame 065610/0460 →
NOTICE OF GRANT OF SECURITY INTEREST IN INTELLECTUAL PROPERTY Recorded Dec 22, 2017
From: OCERA THERAPEUTICS, INC.
To: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
Reel/Frame 044949/0634 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 15, 2015
From: TRANZYME PHARMA INC.
To: TRANZYME HOLDINGS ULC
Reel/Frame 037297/0405 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 15, 2015
From: TRANZYME HOLDINGS ULC
To: OCERA THERAPEUTICS INC.
Reel/Frame 037297/0504 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 3, 2009
From: MARSAULT, ERIC; OUELLET, LUC; HOVEYDA, HAMID R.
To: TRANZYME PHARMA INC.
Reel/Frame 022201/0168 →